Medscape November 13, 2024

(Reuters) -Hims & Hers Health on Wednesday launched a tracker for popular weight-loss and diabetes drugs that allows patients to share details about their challenges finding treatments such as Novo Nordisk’s Wegovy.

The telehealth firm said it would share the information with the U.S. Food and Drug Administration about shortages of the brand-name treatments, it said.

The FDA declined to comment.

WHY IT’S IMPORTANT

Americans are still eagerly seeking prescriptions for Eli Lilly and Novo’s weight-loss and diabetes drugs but cannot always fill them because of supply issues and insurance hurdles, according to their doctors.

Branded GLP-1 drugs from Novo and Lilly have been short in supply for most of this year, fuelling demand for compounded weight-loss treatments created by...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Digital Health, Technology, Telehealth
Related Articles:
Telehealth groups call for urgent action as Medicare flexibility deadline looms
Health care package winners and losers
Wisp Teams Up with Nourish to Combine GLP-1s with Nutrition Counseling
Temporary Federal Funding Bill Addresses SUPPORT Act Reauthorization, Ghost Networks and Telehealth Flexibilities
Stopgap funding bill includes sweeping PBM reform, preserves telehealth flexibilities

Share This Article